Shares of Laurus Labs were trading up by 0.91% at ₹672.65 on June 16 after India’s pharma export data for May 2025 revealed a strong performance by the company. According to official trade data, Laurus Labs’ exports surged 104% year-on-year for the month, more than doubling compared to May 2024.
This significant growth comes as a major boost for investor sentiment, with Laurus seen as a key beneficiary of increasing global demand for Indian pharmaceutical formulations and APIs. The stock hit an intraday high of ₹674.40 in early trade, compared to the previous close of ₹666.60.
The company, which has a market cap of ₹362.80 billion, continues to benefit from robust demand in regulated markets and a healthy product pipeline. With a P/E ratio above 100, Laurus remains one of the most closely watched pharma names in the export-oriented healthcare sector.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
